Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

María Julia

Cura

,

MD

Dermatologist
Hospital Italiano de Buenos Aires
Buenos Aires
,
Argentina
2024 Fellow
IPC Jr. Councilor
Request an Update
Dra. María Julia Cura is a co-leader of the psoriasis team at the Department of Dermatology, Hospital Italiano, Buenos Aires, Argentina. She is a dermatology professor at the National University of the Center (UNICEN) and is actively involved in teaching activities for dermatology residents and peers. She is a member of the Argentine Society of Dermatology (SAD) and the Argentine Society of Psoriasis (SOARPSO).

Dra. Cura has been engaged in clinical research since her residency and is completing a master’s in clinical research. She has presented at numerous national and international congresses and has published her research in peer-reviewed journals. She also participates in Project ECHOⓇ Psoriasis Argentina, a tele-mentoring initiative to empower dermatologists and expand access to best practices in psoriasis care. Dra. Cura has also contributed to developing a virtual community for psoriasis patients and has participated in podcasts focused on the disease. She has received multiple grants and scholarships, including the Strauss & Katz 2019 Scholarship to attend the American Academy of Dermatology (AAD) Annual Meeting, the 6th Congress of the Skin Inflammation & Psoriasis International Network (SPIN), the XXXV and XXXVI Annual Meetings of Latin American Dermatologists (RADLA), the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting and Trainee Symposium 2020, and the Imrich Sarkany Scholarship to attend the 2025 EADV Congress. She was also awarded the “Young Dermatologist Award 2018” by the Argentine Society of Dermatology.

In 2024, Dr. Cura was selected as an IPC International Fellow and completed her fellowship under the mentorship of IPC Councilor Professor Diamant Thaçi at the University of Lübeck, Germany.
Last Updated:
06/30/2025

Areas of Interest

Switching and dose reduction of biologics and small molecules; Dengue in psoriasis

IPC Committees / Groups

Latin America Working Group, Palmoplantar Pustulosis (PPP) Working Group

Languages Spoken

English, Spanish
Recent publications

Featured

Video

Paradoxical Psoriasis.

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including…

Watch Video

Page

Palmoplantar Pustulosis: Why Current Treatments Still Fall Short.

This expert overview by IPC Junior Councilor María Julia Cura examines palmoplantar pustulosis as a distinct…

View Report

Blog

How Psoriasis Severity Is Defined, And What NPF’s Endorsement of IPC’s Framework Means.

Learn how psoriasis severity is defined and what NPF’s endorsement of IPC’s framework means for classifying mild…

Read More

Blog

Honoring Professor Hervé Bachelez for His Service on the IPC Board.

The International Psoriasis Council recognizes Professor Hervé Bachelez, MD, PhD, for his years of service on the IPC…

Read More

Blog

Shaping the Future of Psoriasis Care: IPC's 2025 International Fellows.

Discover how the 2025 IPC International Fellows navigated a year of global learning, collaboration, and growth to help…

Read More

Video

Case Presentation II: Special Populations.

IPC Junior Councilor María Julia Cura presents a challenging case of an elderly patient with psoriasis in high-impact…

Watch Video

PDF

A Report from the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress.

Key takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…

View Report

Blog

A Year of Growth and Collaboration: IPC's 2024 International Fellows.

The 2024 IPC International Fellows reflect on their global dermatological journey, sharing their unique experiences,…

Read More

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026